ARMATA PHARMACEUTICALS, INC. Comprehensive Income
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Comprehensive Income of $19.30 million for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-14.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2014-11-14
- ARMATA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2014-09-30 was $19.30M.
- ARMATA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2014-06-30 was $15.39M.
- ARMATA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2014-03-31 was -$12.03M.
- ARMATA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2013-12-31 was $749.00K.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|
| 2014-09-30 | $19.30M 10-Q · filed 2014-11-14 | $34.68M derived: sum of 2 quarters · filed 2014-11-14 | $22.65M 10-Q · filed 2014-11-14 | $23.40M derived: sum of 4 quarters · filed 2014-11-14 | ||
| 2014-06-30 | $15.39M 10-Q · filed 2014-09-12 | $3.35M 10-Q · filed 2014-09-12 | $4.10M derived: sum of 3 quarters · filed 2014-09-12 | -$39.82M derived: sum of 4 quarters · filed 2014-11-14 | ||
| 2014-03-31 | -$12.03M 10-Q · filed 2014-09-12 | -$10.15M 10-Q · filed 2014-05-20 | -$11.28M derived: sum of 2 quarters · filed 2014-09-12 | -$55.20M derived: sum of 3 quarters · filed 2014-11-14 | -$67.86M derived: sum of 4 quarters · filed 2014-11-14 | |
| 2013-12-31 | $749.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2014-09-12 | -$43.17M derived: sum of 2 quarters · filed 2014-11-14 | -$55.83M derived: sum of 3 quarters · filed 2014-11-14 | -$57.61M 10-Q · filed 2014-09-12 | -$55.82M 10-Q · filed 2014-05-20 | |
| 2013-09-30 | -$43.92M 10-Q · filed 2014-11-14 | -$56.58M derived: sum of 2 quarters · filed 2014-11-14 | -$58.36M 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | -$12.65M 10-Q · filed 2014-09-12 | -$14.39M 10-Q · filed 2014-09-12 | ||||
| 2013-03-31 | -$1.73M 10-Q · filed 2014-09-12 | -$1.73M 10-Q · filed 2014-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |